Bleichroeder Acquisition Corp. II filings document the company’s SPAC structure, Nasdaq-listed securities, material-event reports, governance changes, and capital-structure disclosures. The records identify the issuer as a Cayman Islands exempted company with Class A ordinary shares under BBCQ and redeemable warrants under BBCQW.
The company’s 8-K disclosures include board and management changes, director appointments, and other material-event reporting. Its filings also state emerging growth company status and describe the warrant terms and ordinary-share structure that define the public securities associated with the blank-check issuer.
Bleichroeder Acquisition II and Pasqal are progressing a proposed business combination that would bring Pasqal public. Pasqal plans a U.S. Nasdaq listing and a later Euronext listing. The companies describe a $52.84 million investment and creation of 51 jobs for a Seoul R&D center.
Pasqal highlights its neutral-atom quantum systems (about 200 qubits shown), manufacturing cadence of roughly 9–12 months per unit, production capacity expansions including a Canadian facility, and customer deployments with GENCI, Aramco and European partners. Statements include forward-looking qualifiers and a Form F-4 registration process.
Pasqal announced integration of NVIDIA CUDA-Q into its QRMI runtime, making Pasqal neutral-atom quantum processors schedulable as native accelerators within Slurm-based HPC workflows. The integration permits CUDA-Q workloads to be orchestrated alongside CPUs and GPUs via standard Slurm job submission, allocation, authentication, and monitoring. Pasqal says QRMI is hardware-, modality- and vendor-agnostic and that the capability is available on Pasqal’s cloud platform and planned for on-premises deployment at CINECA with the Leonardo pre-exascale supercomputer. The announcement follows Pasqal’s path to a business combination with Bleichroeder Acquisition Corp. II.
Bleichroeder Acquisition Corp., a Cayman Islands-based blank check company, filed its annual report describing progress toward completing its first business combination. The company targets technology, media and telecommunications and other sectors undergoing digital transformation.
After the reporting period, it completed an IPO on January 9, 2026, selling 28,750,000 units at $10.00 each and placing $287,500,000 into a trust account, alongside a private sale of 7,750,000 private placement warrants. The SPAC must close a business combination by January 9, 2028 or return trust funds to public shareholders.
On February 28, 2026, it signed a Business Combination Agreement with Pasqal Holding SAS, expected to be funded by the trust and a PIPE, with closing targeted for the second half of 2026, subject to regulatory and shareholder approvals. As of March 16, 2026, there were 28,750,000 Class A and 9,583,333 Class B ordinary shares outstanding, no material litigation, and the company highlighted cybersecurity and SPAC-specific regulatory risks.
Bleichroeder Acquisition Corp. II disclosed an article reporting that Pasqal Holding SAS plans a business combination with Bleichroeder that targets a dual listing on the Nasdaq and Euronext Paris and a valuation of $2 billion. Pasqal seeks €340 million in financing in two tranches, including a €170 million fundraise from Parkway, Quanta Computer, LG Electronics and CMA CGM and a €170 million convertible private placement. The company plans a SPAC path to the Nasdaq in 2026 and preparatory work for a Paris IPO in 2026 or 2027. Pasqal expects to launch its Vela machine in 2026 with about 250 qubits and aims to double production capacity within 24 months and pursue a fault-tolerant quantum computer by 2030.
Bleichroeder Acquisition Corp. II entered into a Business Combination Agreement to merge with Pasqal, valuing Pasqal at $2.0 billion pre-money. The transaction contemplates a French reincorporation merger and a fusion-absorption merger to form New Pasqal, and is expected to close in the second half of 2026, subject to customary closing conditions including shareholder and regulatory approvals and listing on Nasdaq.
The deal includes a concurrent private placement: a $250 million aggregate principal amount of senior unsecured convertible bonds (sold for an aggregate purchase price of $200 million reflecting a 20.0% original issue discount) and Investment Warrants equal to 125% of the initial convertible shares. Convertible bonds carry interest at 10.0% per annum with PIK mechanics, an initial conversion price of $12.00, and customary protective and redemption features.
Bleichroeder Acquisition Corp. II agreed to merge with French quantum computing company Pasqal Holding SAS, valuing Pasqal at a $2.0 billion pre-money equity value and targeting closing in the second half of 2026, subject to shareholder, regulatory and listing approvals.
The deal includes a private investment in $250 million principal senior unsecured convertible bonds and related warrants, sold for $200 million (20% discount), bearing 10% cash interest and initially convertible at $12.00 per share with anti-dilution protections and optional redemptions and calls.
Closing conditions include at least $150 million cash for the combined company, Nasdaq listing of New Pasqal shares and warrants, and delivery of PCAOB-audited financials. Sponsor and key Pasqal shareholders entered support, lock-up and registration rights agreements to back the transaction and govern post-merger share sales.
Bleichroeder Acquisition Corp. II disclosed a proposed Business Combination to take French quantum computing firm Pasqal public via a SPAC merger. The announcement cites a €340 million fundraise announced on March 4, including €170 million in private funds and a €170 million convertible financing commitment, valuing Pasqal at €2 billion. The combined company is planned to list on Nasdaq with a potential Euronext listing targeted in 2026 or 2027. The filing notes customary forward-looking risk disclosures and says a Form F-4 registration/proxy will be filed with the SEC.
Bleichroeder Acquisition Corp. II and Pasqal announced that Pasqal has secured expected total funding of at least €340 million, comprising a €170 million private financing round and an approximately €170 million (USD200 million) committed convertible financing in connection with their planned business combination announced on March 4, 2026. The communication states this financing is the first step toward Pasqal’s intended dual listing on Nasdaq and Euronext Paris and says the company will use the capital to scale production, expand R&D, and strengthen global deployment.
The notice explains that a registration statement on Form F-4 will be filed and that shareholders will receive a definitive proxy/prospectus after effectiveness; it cautions that the planned combination and financing are subject to customary approvals and risks.
Bleichroeder Acquisition Corp. II announced a proposed Business Combination to merge with Pasqal Holding SAS. The agreement values the combined company at $2 billion pre-money, includes a $200 million convertible financing and up to $289 million of additional proceeds dependent on investor redemptions. The transaction assigns a pro forma market capitalization of approximately $2.6 billion and is expected to close in the second half of the year. The merger will be submitted to Bleichroeder shareholders and Bleichroeder intends to file a Registration Statement on Form F-4; consummation is subject to shareholder and regulatory approvals.
Bleichroeder Acquisition Corp. II disclosed a March 4, 2026 LinkedIn communication from Pasqal Holding SAS about their proposed business combination and related financing and corporate plans.
Pasqal described accelerated commercialization, geographic expansion across Europe, Asia Pacific, North America and the Middle East, and stated an initial NASDAQ listing expected in 2026. The communication includes standard forward-looking statements and notes that a Form F-4 registration statement and definitive proxy/prospectus will be filed; shareholder approval and regulatory conditions apply, including that consummation is subject to required regulatory approvals.